Trial Outcomes & Findings for Positive Pressure Treatment of Obstructive Sleep Apnea (NCT NCT00636181)

NCT ID: NCT00636181

Last Updated: 2019-08-13

Results Overview

The Apnea-Hyopnea Index is the number of average number of apneas (complete pauses in breathing lasting at least 10 seconds) and hypopneas (decreases in airflow lasting at least 10 seconds) per hour of sleep. This data was compared from the polysomnography (sleep study) data after the first night of device use and at 180 days

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

168 participants

Primary outcome timeframe

Baseline and 180 Days

Results posted on

2019-08-13

Participant Flow

Patients who completed routine clinical diagnostic visit and CPAP titration polysomnography (PSG) at 5 international sleep centers were consecutively recruited for the study. These patients were approached with information on the study and were asked to consent to participate.

168 participants were enrolled into the study. However 4 participants were excluded from the analysis and demographic data because they withdrew from the trial prior to any study procedures.

Participant milestones

Participant milestones
Measure
Auto Aflex
auto adjusting positive pressure therapy with AFLEX Auto AFlex: Positive pressure therapy treatment
Auto CPAP
auto adjusting positive pressure therapy Auto CPAP: Positive pressure therapy treatment
CPAP
continuous positive airway pressure CPAP: Positive pressure therapy treatment
Overall Study
STARTED
54
53
57
Overall Study
COMPLETED
46
47
47
Overall Study
NOT COMPLETED
8
6
10

Reasons for withdrawal

Reasons for withdrawal
Measure
Auto Aflex
auto adjusting positive pressure therapy with AFLEX Auto AFlex: Positive pressure therapy treatment
Auto CPAP
auto adjusting positive pressure therapy Auto CPAP: Positive pressure therapy treatment
CPAP
continuous positive airway pressure CPAP: Positive pressure therapy treatment
Overall Study
Withdrawal by Subject
8
6
10

Baseline Characteristics

Positive Pressure Treatment of Obstructive Sleep Apnea

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Auto Aflex
n=54 Participants
auto adjusting positive pressure therapy with AFLEX Auto AFlex: Positive pressure therapy treatment
Auto CPAP
n=53 Participants
auto adjusting positive pressure therapy Auto CPAP: Positive pressure therapy treatment
CPAP
n=57 Participants
continuous positive airway pressure CPAP: Positive pressure therapy treatment
Total
n=164 Participants
Total of all reporting groups
Age, Continuous
49.1 years
STANDARD_DEVIATION 11.6 • n=5 Participants
48.3 years
STANDARD_DEVIATION 10.0 • n=7 Participants
48.8 years
STANDARD_DEVIATION 12.0 • n=5 Participants
48.9 years
STANDARD_DEVIATION 11.2 • n=4 Participants
Sex: Female, Male
Female
13 Participants
n=5 Participants
13 Participants
n=7 Participants
14 Participants
n=5 Participants
40 Participants
n=4 Participants
Sex: Female, Male
Male
41 Participants
n=5 Participants
40 Participants
n=7 Participants
43 Participants
n=5 Participants
124 Participants
n=4 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
0 Participants
n=4 Participants
Race (NIH/OMB)
Asian
3 Participants
n=5 Participants
1 Participants
n=7 Participants
0 Participants
n=5 Participants
4 Participants
n=4 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
0 Participants
n=4 Participants
Race (NIH/OMB)
Black or African American
3 Participants
n=5 Participants
8 Participants
n=7 Participants
8 Participants
n=5 Participants
19 Participants
n=4 Participants
Race (NIH/OMB)
White
46 Participants
n=5 Participants
42 Participants
n=7 Participants
47 Participants
n=5 Participants
135 Participants
n=4 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
0 Participants
n=4 Participants
Race (NIH/OMB)
Unknown or Not Reported
2 Participants
n=5 Participants
2 Participants
n=7 Participants
2 Participants
n=5 Participants
6 Participants
n=4 Participants
Region of Enrollment
United States
39 participants
n=5 Participants
44 participants
n=7 Participants
45 participants
n=5 Participants
128 participants
n=4 Participants
Region of Enrollment
Germany
15 participants
n=5 Participants
9 participants
n=7 Participants
12 participants
n=5 Participants
36 participants
n=4 Participants
Apnea-Hypopnea Index
36.87 events/hour
STANDARD_DEVIATION 30 • n=5 Participants
37.29 events/hour
STANDARD_DEVIATION 31.1 • n=7 Participants
41.08 events/hour
STANDARD_DEVIATION 31.57 • n=5 Participants
38.52 events/hour
STANDARD_DEVIATION 30.6 • n=4 Participants

PRIMARY outcome

Timeframe: Baseline and 180 Days

Population: During the course of the study 24 participants withdrew from the study.

The Apnea-Hyopnea Index is the number of average number of apneas (complete pauses in breathing lasting at least 10 seconds) and hypopneas (decreases in airflow lasting at least 10 seconds) per hour of sleep. This data was compared from the polysomnography (sleep study) data after the first night of device use and at 180 days

Outcome measures

Outcome measures
Measure
Auto Aflex
n=54 Participants
auto adjusting positive pressure therapy with AFLEX Auto AFlex: Positive pressure therapy treatment
Auto CPAP
n=53 Participants
auto adjusting positive pressure therapy Auto CPAP: Positive pressure therapy treatment
CPAP
n=57 Participants
continuous positive airway pressure CPAP: Positive pressure therapy treatment
Apnea-Hypopnea Index
Baseline
6.09 events/hour
Standard Deviation 7.20
3.54 events/hour
Standard Deviation 4.39
3.24 events/hour
Standard Deviation 3.46
Apnea-Hypopnea Index
180 Days
1.26 events/hour
Standard Deviation 2.92
0.67 events/hour
Standard Deviation 0.93
1.04 events/hour
Standard Deviation 1.28

SECONDARY outcome

Timeframe: 180 days

Population: During the course of the study 24 participants withdrew from the study.

The average hours of nightly use is the average number of hours the participant used there device overnight at home during the study.

Outcome measures

Outcome measures
Measure
Auto Aflex
n=46 Participants
auto adjusting positive pressure therapy with AFLEX Auto AFlex: Positive pressure therapy treatment
Auto CPAP
n=47 Participants
auto adjusting positive pressure therapy Auto CPAP: Positive pressure therapy treatment
CPAP
n=47 Participants
continuous positive airway pressure CPAP: Positive pressure therapy treatment
Average Hours of Nightly Use.
4.44 hours
Standard Deviation 1.98
4.63 hours
Standard Deviation 1.75
4.40 hours
Standard Deviation 2.02

SECONDARY outcome

Timeframe: Baseline and 180 Days

Population: During the course of the study 24 participants withdrew from the study.

Psychomotor Vigilance Task-PVT is a 10-min attention/vigilance test. To measure trends of vigilance after 180 days of home use randomized sleep apnea trial. This measured how quickly participants reacted to visual stimulus and counted number of lapses. Lapses (errors of omission) are measured or usually defined as reaction Times ≥ 500 ms.

Outcome measures

Outcome measures
Measure
Auto Aflex
n=54 Participants
auto adjusting positive pressure therapy with AFLEX Auto AFlex: Positive pressure therapy treatment
Auto CPAP
n=53 Participants
auto adjusting positive pressure therapy Auto CPAP: Positive pressure therapy treatment
CPAP
n=57 Participants
continuous positive airway pressure CPAP: Positive pressure therapy treatment
Psychomotor Vigilance Task - Number of Lapses
Baseline
2.15 number of lapses
Standard Deviation 3.74
3.41 number of lapses
Standard Deviation 7.75
2.15 number of lapses
Standard Deviation 4.10
Psychomotor Vigilance Task - Number of Lapses
180 days
0.98 number of lapses
Standard Deviation 2.14
0.96 number of lapses
Standard Deviation 1.32
1.30 number of lapses
Standard Deviation 3.32

SECONDARY outcome

Timeframe: Baseline and 180 Days

Population: During the course of the study 24 participants withdrew from the study.

FOSQ is a quality of life questionnaire for sleep disorders. It's a 30 question survey with 5 subgroups: general productivity (8 questions), social outcome (2 questions),activity level (9 questions), vigilance (7 questions) and intimate relationships \& sexual activity (4 questions). Scores are provided on a 0 to 4 scale: 0- I don't do this activity for other reasons or missing response 1- Yes, extreme difficulty 4- no difficulty The average score was calculated based upon average sub-scores. The total score was,calculated using the mean of the subscale scores and multiplying the mean by the number of subscales. The range of scores for the total score is 5-20. The measures are designed to assess the impact of disorders of excessive sleepiness on activities of everyday living and the extent to which these abilities are improved by effective treatment. The lower the score the more difficulty a person has carrying out certain activities because they are too sleepy or tired.

Outcome measures

Outcome measures
Measure
Auto Aflex
n=54 Participants
auto adjusting positive pressure therapy with AFLEX Auto AFlex: Positive pressure therapy treatment
Auto CPAP
n=53 Participants
auto adjusting positive pressure therapy Auto CPAP: Positive pressure therapy treatment
CPAP
n=57 Participants
continuous positive airway pressure CPAP: Positive pressure therapy treatment
Functional Outcomes of Sleep Questionnaire (FOSQ)
baseline
15.17 score on a scale
Standard Deviation 3.13
15.85 score on a scale
Standard Deviation 2.94
14.57 score on a scale
Standard Deviation 3.97
Functional Outcomes of Sleep Questionnaire (FOSQ)
180 days
17.11 score on a scale
Standard Deviation 2.22
17.78 score on a scale
Standard Deviation 2.06
16.74 score on a scale
Standard Deviation 3.26

SECONDARY outcome

Timeframe: Baseline and 180 Days

Population: During the course of the study 24 participants withdrew from the study.

Attitudes Toward Use Questionnaire (ATUQ) a self-efficacy scale based on psychological theories of behavior change and modified from one developed by Stepnowsky and Marler this outcome focused on confidence, expectations and importance. Confidence is a 5 question survey, it is measured on a scale of 1 to 5 1- disagree completely and 5 being agree completely. The scores range from 5 to 25 with 25 being extremely confident. Importance is a 11 question survey, it is measured on a scale of 1 to 5 1- disagree completely and 5 being agree completely. The importance ATU was combined with Exceptions survey, which is 4 questions. The expectations survey is measured on a scale of 1 to 5, with 1 being not at all effective and 5 extremely effective. The scores range from 15 to 75 with 75 being extremely important/ extremely effective.

Outcome measures

Outcome measures
Measure
Auto Aflex
n=54 Participants
auto adjusting positive pressure therapy with AFLEX Auto AFlex: Positive pressure therapy treatment
Auto CPAP
n=53 Participants
auto adjusting positive pressure therapy Auto CPAP: Positive pressure therapy treatment
CPAP
n=57 Participants
continuous positive airway pressure CPAP: Positive pressure therapy treatment
Attitudes Toward Use
Confidence at baseline
20.7 units on a scale
Standard Deviation 3.6
21.8 units on a scale
Standard Deviation 2.9
22.3 units on a scale
Standard Deviation 2.6
Attitudes Toward Use
Confidence at 180 days
20.7 units on a scale
Standard Deviation 5.2
22.5 units on a scale
Standard Deviation 3.3
21.9 units on a scale
Standard Deviation 4.1
Attitudes Toward Use
Expectations + Importance at baseline
49.8 units on a scale
Standard Deviation 7.4
48.4 units on a scale
Standard Deviation 5.0
48.1 units on a scale
Standard Deviation 6.9
Attitudes Toward Use
Expectations + Importance at 180 days
47.2 units on a scale
Standard Deviation 5.3
46.7 units on a scale
Standard Deviation 5.8
46.9 units on a scale
Standard Deviation 5.0

SECONDARY outcome

Timeframe: 30, 90, and 180 days

Population: During the course of the study 24 participants withdrew from the study.

visual analog scales where used to assess the question "in the last month how do you rate the overall comfort of the mask"? 0 = very uncomfortable to 100 = very comfortable

Outcome measures

Outcome measures
Measure
Auto Aflex
n=54 Participants
auto adjusting positive pressure therapy with AFLEX Auto AFlex: Positive pressure therapy treatment
Auto CPAP
n=53 Participants
auto adjusting positive pressure therapy Auto CPAP: Positive pressure therapy treatment
CPAP
n=57 Participants
continuous positive airway pressure CPAP: Positive pressure therapy treatment
Subjective Assessment of Therapy Comfort.
30 days
50.8 units on a scale
Standard Deviation 21.5
57.9 units on a scale
Standard Deviation 20.5
53.9 units on a scale
Standard Deviation 18.9
Subjective Assessment of Therapy Comfort.
90 days
53.8 units on a scale
Standard Deviation 25.1
61.0 units on a scale
Standard Deviation 15.0
59.2 units on a scale
Standard Deviation 18.3
Subjective Assessment of Therapy Comfort.
180 days
54.7 units on a scale
Standard Deviation 21.7
60.1 units on a scale
Standard Deviation 14.7
60.6 units on a scale
Standard Deviation 17.9

SECONDARY outcome

Timeframe: Baseline and 180 days

Population: During the course of the study 24 participants withdrew from the study.

Epworth Sleepiness Scale is a test that measures sleepiness during daily life activities. This is an 8 question survey. Scores are provided on a 0 to 3 scale: 0 = no chance of dozing 1. = slight chance of dozing 2. = moderate chance of dozing 3. = high chance of dozing Scores range from 0 to 24. The higher the total number, the higher the overall sleepiness.

Outcome measures

Outcome measures
Measure
Auto Aflex
n=54 Participants
auto adjusting positive pressure therapy with AFLEX Auto AFlex: Positive pressure therapy treatment
Auto CPAP
n=53 Participants
auto adjusting positive pressure therapy Auto CPAP: Positive pressure therapy treatment
CPAP
n=57 Participants
continuous positive airway pressure CPAP: Positive pressure therapy treatment
Epworth Sleepiness Scale
Baseline
10.43 units on a scale
Standard Deviation 5.25
10.49 units on a scale
Standard Deviation 4.59
12.27 units on a scale
Standard Deviation 5.94
Epworth Sleepiness Scale
180 Days
6.93 units on a scale
Standard Deviation 4.30
7.02 units on a scale
Standard Deviation 4.66
7.87 units on a scale
Standard Deviation 5.53

Adverse Events

Auto Aflex

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Auto CPAP

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

CPAP

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Clete A. Kushida, MD, PhD

Stanford Sleep Medicine Center

Phone: (650) 721-7560

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place